ProCE Banner Activity

Virtual World Congress on Lung Cancer 2020: Experts Discuss Their Top Studies in NSCLC

Conference Coverage
Clinical Thought
In this commentary, 2 experts share thoughts on their picks for top studies in early-stage and advanced NSCLC presented at the virtual WCLC 2020.

Released: March 16, 2021

Expiration: March 15, 2022

No longer available for credit.

Share

Faculty

Jamie E. Chaft

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Nicolas Girard

Nicolas Girard, MD, PhD

Chair, Medical Oncology Department, Institut Curie
Paris, France
Professor, UVSQ, Paris Saclay University
Versailles, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Janssen Pharmaceutica NV

Jazz Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Takeda Oncology

Faculty Disclosure

Primary Author

Jamie E. Chaft, MD

Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Jamie E. Chaft, MD, has disclosed that she has received consulting fees and funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Flame Biosciences, Genentech, Janssen, Merck, and Novartis.

Nicolas Girard, MD, PhD

Chair, Medical Oncology Department, Institut Curie
Paris, France
Professor, UVSQ, Paris Saclay University
Versailles, France

Nicolas Girard, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Roche, Sanofi, and Teva, and funds for research support from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche.